SMS Pharma revenue down 9%
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company is focussed on increasing the capacity utilizations while controlling costs
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company sees the business reaching $100mn
Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Subscribe To Our Newsletter & Stay Updated